By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Biotechnology have been published. According to news reporting from Genoa, Italy, by NewsRx journalists, research stated, "The practice of administering sublingual immunotherapy for respiratory allergy is gaining more and more diffusion worldwide as a consequence of the robust demonstration of clinical efficacy and safety provided by recent high-powered and well-designed studies, confirming for individual seasonal allergens the results of previous metanalyses in adult and pediatric populations. Preliminary evidence derives from recent rigorous trials on perennial allergens, like house dust mites, and specifically designed studies addressed the benefits on asthma."
The news correspondents obtained a quote from the research from the University of Genoa, "Emerging research suggests that SLIT may have a future role in other allergic conditions such as atopic dermatitis, food, latex and venom allergy. Efforts to develop a safer and more effective SLIT for inhalant allergens have led to the development of allergoids, recombinant allergens and formulations with adjuvants and substances targeting antigens to dendritic cells that possess a crucial role in initiating immune responses. The high degree of variation in the evaluation of clinical effects and immunological changes requires further studies to identify the candidate patients to SLIT and biomarkers of short and long term efficacy."
According to the news reporters, the research concluded: "Appropriate management strategies are urgently needed to overcome the barriers to SLIT compliance."
For more information on this research see: Sublingual Immunotherapy: Recent Advances. Allergology International, 2013;62(4):415-423. Allergology International can be contacted at: Japanese Society Allergology, My Bldg 4F, 1-13-3, Ueno, Taito-Ku, Tokyo, 110-0005, Japan. (Wiley-Blackwell - www.wiley.com/; Allergology International - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1440-1592)
Our news journalists report that additional information may be obtained by contacting E. Compalati, University of Genoa, DIMI, Allergy & Resp Dis Clin, I-16132 Genoa, Italy. Additional authors for this research include F. Braido and G.W. Canonica (see also technology.html">Biotechnology).
Keywords for this news article include: Antigens, Biotechnology, Genoa, Italy, Europe, Allergens, Immunology, Immunotherapy, Immunomodulation
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC